Special Issue "Immunotherapy against Myeloma"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 320
Special Issue Editors
Interests: chronic lymphocytic leukemia; coronavirus; ACE2
Special Issues, Collections and Topics in MDPI journals
Interests: chronic lymphocytic leukemia; coronavirus; myeloma
Special Issue Information
Dear Colleagues,
Mono- and bi-specific monoclonal antibodies and CAR-T are a mainstay of a new anti-myeloma era. Since the availability of several competing association therapies has caused therapeutic algorithms to rapidly evolve, the final scope of this Issue is to settle the hurdles to the widespread adoption of immunotherapies for multiple myeloma. This Special Issue will also host the debate on modern clinical endpoints for clinical trials and drug approval in the myeloma field.
Dr. Monia Marchetti
Dr. Federico Monaco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- monoclonal antibodies
- daratumumab
- elotuzumab
- isatuximab
- CAR-T
- meta-analysis
- evidence-based medicine
- cost-effectiveness analysis
